XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. (2015). Acta Medica Philippina, 49(2). https://doi.org/10.47895/amp.v49i2.988